RCT | Baricitinib vs. placebo for systemic lupus erythematosus

Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-I) – The Lancet (link to abstract – $ for full-text)

See also: Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-II) – The Lancet (link to abstract – $ for full-text)

Commentary: Benefit of baricitinib for treatment of patients with moderately to severely active SLE is unclear – Monash University

Commentary on Twitter

NEW in @TheLancet—Two phase 3 trials of #baricitinib for systemic #lupus erythematosus #SLE-BRAVE-I > https://t.co/wX0w7w4Glm

SLE-BRAVE-II > https://t.co/56sd0DmjN9

Linked Comment by Laura Durcan (@Rheum2improve) & Grainne Murphy > https://t.co/RBJYEcSNle pic.twitter.com/XW6sXQnSn9

— The Lancet Rheumatology (@TheLancetRheum) February 27, 2023